Diagnosis of sleepiness, fatigue and depression in patients with myasthenia gravis

Introduction. Examination of excessive daytime sleepiness, fatigue and depression in patients with myasthenia gravis is important for differential diagnosis of other disorders, and adds to a comprehensive clinical assessment.

Objective. The aim is a comprehensive assessment of sleepiness, fatigue and depression and evaluation of the impact of autoimmune comorbidity on these symptoms in myasthenia gravis patients, using newly validated Russian versions of international questionnaires. The present article aims at familiarizing a wider Russian-speaking audience of specialists in the field of neuromuscular disease and sleep medicine with the main findings of our previously published work.

Materials and methods. The study included 73 patients with MG and 230 control subjects. For sleepiness, fatigue and depression evaluation were used: Fatigue Severity Scale (FSS), Fatigue Impact Scale (FIS) (cognitive / physical / psychosocial subscales), Epworth Sleepiness Scale (ESS), Beck Depression Inventory (BDI) (cognitive-affective and somatic domains), Spielberger–Khanin State Trait Anxiety Inventory (STAI).

Results. The Fatigue Severity Scale and Fatigue Impact Scale showed good psychometric properties and can be used to identify distinct aspects of fatigue in patients with myasthenia gravis. The studied patient cohort revealed clinically significant fatigue (69.9 %), excessive daytime sleepiness (15.1 %), moderate to severe depression (20.5 %), a high level of personal (64.4 %) and situational anxiety (27.4 %). Among 13 patients with myasthenia gravis and additional autoimmune comorbidity, there were no significant differences in the severity of sleepiness, fatigue and depression compared with the main group.

Conclusion. The use of self-reported scale of sleepiness, fatigue and depression combined with careful clinical-neurological characterization adds to a more comprehensive view of the patient. The identification of sleepiness, fatigue and depression can guide therapeutic decisions and contributes to a better patient care. The presence of concomitant autoimmune pathology in patients with myasthenia gravis does not seem to increase the severity of sleepiness, fatigue and depression.

1. Sanadze А.G. Myasthenia gravis and myasthenic syndromes. Moscow: GEOTAR-Media, 2017. 256 р. (In Russ.).

2. Gusev E.I., Gekht A.B. Clinical recommendations for the diagnosis and treatment of myasthenia gravis. Presidium of the All-Russian society of neurologists. Moscow, 2013. 29 p. (In Russ.).

3. Kluger B.M., Krupp L.B., Enoka R.M. Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy. Neurology 2013;80(4):409–16. DOI: 10.1212/WNL.0b013e31827f07be. PMID: 23339207.

4. Penner I.K., Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol 2017;13(11):662–75. DOI: 10.1038/nrneurol.2017.117. PMID: 29027539.

5. Tran C., Bril V., Katzberg H.D., Barnett C. Fatigue is a relevant outcome in patients with myasthenia gravis. Muscle Nerve 2018;58(2):197–203. DOI: 10.1002/mus.26069. PMID: 29342314.

6. Shinkai K., Ohmori O., Ueda N. et al. A case of myasthenia gravis preceded by major depression. J Neuropsychiatry Clin Neurosci 2001;13:116–7. DOI: 10.1176/jnp.13.1.116. PMID: 11207344.

7. Rüegg S.J., Dirnhofer S., BuitragoTellez C.H. et al. Life-threatening myasthenia gravis masked by a psychiatric disorder. Swiss Arch Neurol Psychiatr 2007;158:150–4. DOI:10.4414/sanp.2007.01850. PMID: 78365098.

8. Martínez-Lapiscina E.H., Erro M.E., Ayuso T., Jericó I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve 2012;46(2):174–80. DOI: 10.1002/mus.23296. PMID: 22806365.

9. Oliveira E.F., Nacif S.R., Urbano J.J. et al. Sleep, lung function, and quality of life in patients with myasthenia gravis: a crosssectional study. Neuromuscul Disord 2017;27:120–7. DOI: 10.1016/j.nmd.2016.11.015. PMID: 28062220.

10. Quera-Salva M.A., Guilleminault C., Chevret S. et al. Breathing disordersduring sleep in myasthenia gravis.Ann Neurol 1992;31:86–92. DOI: 10.1002/ana.410310116. PMID: 1543353.

11. Gavrilov Y.V., Alekseeva T.M., Kreis O.A. et al. Depression in myasthenia gravis: a heterogeneous and intriguing entity. J Neurol 2020;267(6):1802–11. DOI: 10.1007/s00415-020-09767-7. PMID: 32140868.

12. Krupp L.B., LaRocca N.G., Muir-Nash J., Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–3. DOI: 10.1001/archneur.1989.00520460115022. PMID: 2803071.

13. Valko P.O., Bassetti C.L., Bloch K.E. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008;31:1601–7. DOI: 10.1093/sleep/31.11.1601. PMID: 19014080.

14. Fisk J.D., Ritvo P.G., Ross L. et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(1):79–83. DOI: 10.1093/clinids/18.supplement_1.s79. PMID: 8148458.

15. Alekseeva T.M., Gavrilov Y.V., Kreis O.A. et al. Fatigue in patients with myasthenia gravis. J Neurol 2018;265(10):2312–21. DOI: 10.1007/s00415-018-8995-4. PMID: 30099585.

16. Alekseeva T.M., Kreis O.A., Gavrilov Y.V. et al. Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis. J Neurol 2019;266(8):2027–34. DOI: 10.1007/s00415-019-09374-1. PMID: 31115673.

17. Elsais A., Wyller V.B., Loge J.H., Kerty E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol 2013;13:132. DOI: 10.1186/1471-2377-13-132. PMID: 24088269.

18. Hoffmann S., Ramm J., Grittner U. et al. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav 2016;6(10):e00538. DOI: 10.1002/brb3.538. PMID: 27781147.

19. Smolin A.I. Myasthenia gravis: variants of the clinical course, differentiated treatment and quality of life of patients: Abstract. dis. … сand. med. sciences. Irkutsk, 2015. 23 p. (In Russ.).

20. Jordan B., Schweden T.L.K., Mehl T. et al. Cognitive fatigue in patients with myasthenia gravis. Muscle Nerve 2017;56:449–57. DOI: 10.1002/mus.25540. PMID: 28033668.

21. Fisher J., Parkinson K., Kothari M.J. Selfreported depressive symptoms in myasthenia gravis. J Clin Neuromusc Dis 2003;4:105–8. DOI: 10.1097/00131402-200303000-00001. PMID: 19078699.

22. Suzuki Y., Utsugisawa K., Suzuki S. et al. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open 2011;1:e000313. DOI: 10.1136/bmjopen-2011-000313. PMID: 22184587.

23. Christensen P. B., Jensen T. S., Tsiropoulos I. et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand 1995;91:192–5. DOI: 10.1111/j.1600-0404.1995.tb00432.x. PMID: 7793234.

24. Mao Z.F., Yang L.X., Mo X.A. et al. Frequency of autoimmune diseases in myasthenia gravis: a systematic review. Int J Neurosci 2011;121(3):121–9. DOI: 10.3109/00207454.2010.539307. PMID: 21142828.

25. Pryce C.R., Fontana A. Depression in Autoimmune Diseases. Curr Top Behav Neurosci 2017;31:139–54. DOI: 10.1007/7854_2016_7. PMID: 27221625.